“When one looks beyond these initial challenges, the very real—and not inconsequential—operational and commercial benefits that clinical data standards offer the life sciences industry become apparent. These opportunities can be leveraged to maximize business outcomes for pharma,  biotech, and academia in a number of areas, both in the short-term and long run.”

Read Karim Damji  and Dr. Rebecca Kush’s  commentary on how new clinical data standards can be used to create better business outcomes.

The post Saama SVP, Karim Damji, and Board Advisor, Dr. Rebecca Kush, write for Clinical Informatics News appeared first on Saama Technologies.